Research
Hormonal
PPARα activation via fibrates improves lipid profiles (lowering triglycerides and raising HDL-C) but does not improve glucose homeostasis in patients with type 2 diabetes.
If you have type 2 diabetes and high triglycerides/low HDL, fibrates (PPARα agonists) can help your lipid profile and reduce cardiovascular risk, but they will not lower your blood sugar. You likely still need a medication that targets glucose (like a PPARγ agonist) for diabetes management.
GoodQualifiesHIGH confidence
Fibrate therapy, however, does not change circulating FA concentrations... Fibrates do not improve glucose homeostasis in people with T2D... activation of PPARα improves the lipid profile, whereas activation of PPARγ improves glycemic control and insulin sensitivity.
Why this rating
Based on multiple large clinical outcome trials (HHS, VA-HIT, FIELD, ACCORD) and meta-analyses cited in the review.
Source
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Vanessa Dubois et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci88894
narrative_reviewCited 373×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- PPARγ activation via thiazolidinediones (TZDs) improves glycemic control and insulin sensitivity but causes adverse effects including weight gain, edema, and increased fracture risk.Good
- PPARβ/δ activation improves both lipid profiles and insulin sensitivity by promoting fatty acid oxidation, fiber type switching in muscle, and energy expenditure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →